Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 20,000 shares at $62.96 ($1.3M) on 2026-02-11, disclosed to the SEC on 2026-02-13.
Scheduled sale ($1.3M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.96 | 11,494 | $724K | 57.1% |
| 2 | $63.73 | 7,551 | $481K | 38.0% |
| 3 | $64.99 | 955 | $62K | 4.9% |
| Total | $63.35 avg | 20,000 | $1.3M | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |